Navigation Links
AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
Date:11/29/2011

WELLESLEY HILLS, Mass., Nov. 29, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 277 discriminates against S1P3 receptor by 50-fold and that the S1P1 lead compounds will be offered December 8, 2011 in a sealed bid sale.  These assets were generated by Epix Pharmaceuticals, Inc. and Amgen.

AMG 277 has 57-nM functional EC50 for hS1P1 receptor and discriminates against S1P3 receptor by 50-fold.  It displayed efficacy in a DTH model with ED70 of 1.0 mpk.  AMG 277 was tested in FIH-enabling toxicology studies.    

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – jffinnjr@finnwarnkegayton.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, LLP Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@finnwarnkegayton.com


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... DUBLIN , Feb. 22, 2017  Allergan ... is proud to be a Gold sponsor of ... National Educating America Tour." This tour commemorates AFA,s15 ... availability of services and programs. The tour will ... free memory screenings and displays of the AFA ...
(Date:2/22/2017)... According to a new market research report "Process ... and Services (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO ... market is poised to reach USD 3.30 Billion by 2021 from USD ... 2021. Continue Reading ... ...
(Date:2/22/2017)... 22, 2017 The intersection ... and more prevalent today resulting in identifying and ... as well as other botanicals for discovering the ... marijuana therapies and their applications. Cannabis companies are ... designed to bring the new therapies to the ...
Breaking Medicine Technology:
(Date:2/22/2017)... Charleston, SC (PRWEB) , ... February 22, 2017 , ... ... one of several sponsors of the Medical University of South Carolina (MUSC) Center on ... in Mount Pleasant, SC. “MUSC’s Center on Aging is a tremendous resource in our ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... patient advocates stress that the patient context (age, illness and life choices) should ... to mitigate their occurrence. In addition, all too often, studies regarding ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a ... and spend management, today announced that Keppel Corporation has selected Apptricity Travel and ... , “We are excited to announce the partnership between Keppel and Apptricity ...
(Date:2/21/2017)... ... ... Author Michèle Wolff has a passion for using food as medicine ... about it for optimal health. Wanting to share her knowledge to the world, she ... Solutions ” (published by Balboa Press AU). , This book inspires readers to ...
(Date:2/21/2017)... ... 21, 2017 , ... Tripp Lite, a world-leading manufacturer of ... that meet the most current standards. , The adoption by the Centers for ... Protection Association (NFPA) 101 – Life Safety Code (LSC) and NFPA 99 – ...
Breaking Medicine News(10 mins):